Glenmark Pharmaceuticals , a leading pharmaceutical company, has announced significant corporate actions that are set to impact its shareholders and governance structure.

Interim Dividend Declaration

The Board of Directors of Glenmark Pharmaceuticals has approved an interim dividend of ₹2.50 per equity share. This dividend, based on a face value of ₹1 per equity share, amounts to a total payout of ₹705.50 million.

Shareholders should note the following key dates:

• Record Date: Friday, October 3
• Payment Timeline: Within 30 days from the declaration date

Board Committee Reconstitution

Effective October 1, Glenmark has announced a reshuffle in three of its key board committees:

1. Stakeholders Relationship Committee

• Chairman: Ms. Sona Saira Ramasastry
• Members: Mrs. Cherylann Pinto, Ms. Patricia Andrews

2. Risk Management Committee

• Chairman: Mr. Dipankar Bhattacharjee
• Members: Mr. Glenn Saldanha, Ms. Patricia Andrews, Mr. Anurag Mantri

3. ESG (Environmental, Social and Governance) Committee

• Chairman: Mr. Glenn Saldanha
• Members: Ms. Sona Saira Ramasastry, Ms. Patricia Andrews

These changes in committee structures reflect Glenmark's commitment to robust corporate governance and stakeholder engagement.

Board Meeting Details

The decisions were made during a Board of Directors meeting held on Friday, September 26. The meeting commenced at 10:00 a.m. IST and concluded at 10:21 a.m. IST.

These corporate actions demonstrate Glenmark Pharmaceuticals' focus on shareholder returns and organizational governance.

Glenmark Pharmaceuticals has made a significant move in the oncology space, announcing a $1.1 billion agreement with Hengrui Pharma for the exclusive rights to a cutting-edge HER2-targeting cancer therapy across multiple regions.

Deal Highlights

• Glenmark's wholly-owned subsidiary, Glenmark Specialty S.A. (GSSA), has entered into an exclusive license and collaboration agreement with Hengrui Pharma.
• The agreement covers Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).
• Glenmark will pay an upfront payment of $18.00 million to Hengrui.
• Hengrui is eligible to receive regulatory and commercial milestone payments of up to $1.09 billion.
• Glenmark will also pay royalties to Hengrui based on the net sales of Trastuzumab Rezetecan within the licensed territory.

Geographical Coverage

The deal provides Glenmark with exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide, with notable exceptions including:

• Mainland China
• Hong Kong SAR
• Macao SAR
• Taiwan Region
• USA
• Canada
• Europe
• Japan
• Russia and several CIS countries

Trastuzumab Rezetecan: A Promising Therapy

Trastuzumab Rezetecan (SHR-A1811) is Hengrui's self-developed HER2-targeted ADC, which has shown promising results:

• Approved in China for treating adult patients with HER2 activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC).
• First China-developed ADC approved for HER2-mutated NSCLC.
• New indication for breast cancer accepted by China's NMPA for review.
• Included in the NMPA's Breakthrough Therapy Designation list for nine indications, covering various cancer types.
• Received Orphan Drug Designation from the US FDA for gastric or gastroesophageal junction adenocarcinoma.

Strategic Implications

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Limited, stated, "This partnership aligns strongly with our strategy to bring differentiated, high-value therapies to patients and reinforces our commitment to advancing innovation in areas of significant unmet need."

The collaboration marks a significant step in Glenmark's focused oncology strategy, particularly in complex biologics. It underscores the company's long-term commitment to delivering next-generation therapies across high-burden, underserved geographies.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments. The company focuses on therapeutic areas of respiratory, dermatology, and oncology. With 11 world-class manufacturing facilities across 4 continents and operations in over 80 countries, Glenmark is ranked among the Top 100 biopharmaceutical companies by Scrip 100 and in the Top 50 Generics and biosimilar companies by Generics Bulletin.

This strategic partnership with Hengrui Pharma not only strengthens Glenmark's oncology portfolio but also positions the company to potentially make significant advancements in cancer treatment, particularly in HER2-targeted therapies.